Asked by: Bob Blackman (Conservative - Harrow East)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps are being taken to ensure cumulative drug toxicity and polypharmacy risks are actively monitored in people prescribed sodium valproate.
Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)
There are established systems within the National Health Service to ensure that cumulative drug toxicity and polypharmacy risks are actively monitored in people prescribed sodium valproate. In practice, this involves establishing arrangements for assessing, reviewing, and monitoring the ongoing need for treatments, and, given that sodium valproate is almost invariably initiated in secondary care, clear shared-care arrangements between secondary and primary care clinicians, supported by the involvement of pharmacists, to minimise the risks associated with cumulative drug toxicity and polypharmacy.
Asked by: Bob Blackman (Conservative - Harrow East)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what learning has been implemented following the coroner’s finding that harm from sodium valproate exposure contributed to the death of Jake Aldcroft.
Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)
Everyone who has been harmed from sodium valproate has our deepest sympathies.
Action has been taken to minimise the risk of foetal harm associated with valproate, and to ensure that healthcare professionals are also able to support any babies and families that are affected. The valproate Pregnancy Prevention Programme ensures that women and girls taking valproate understand the potential risks should they become pregnant, are using effective contraception, and are regularly monitored. It is supported by educational materials for healthcare professionals and patients.
The programme was updated in January 2024 to reflect updated Medicines and Healthcare Products Regulatory Agency advice that valproate must not be started in new patients, either male or female, younger than 55 years old, unless two specialists independently consider and document that there is no other effective or tolerated treatment, or there are compelling reasons that the reproductive risks do not apply.
Asked by: Bob Blackman (Conservative - Harrow East)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, whether NHS England plans to commission specialist multidisciplinary services for people affected by sodium valproate exposure, including care coordination, to help reduce emergency admissions and diagnostic times.
Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)
The Independent Medicines and Medical Devices Safety Review, First Do No Harm, identified significant shortcomings in National Health Service care pathways for people harmed by sodium valproate, including fragmented services, limited diagnostic expertise, delays in diagnosis, and inequitable access to multidisciplinary care. NHS England has acknowledged variation in the availability and adequacy of care pathways, the impact of delayed diagnosis and misdiagnosis on long-term outcomes, and the need for improved care coordination for those requiring lifelong support.
In response, NHS England has commissioned a Fetal Exposure to Medicines Services Pilot, being delivered by the Newcastle upon Tyne Hospitals NHS Foundation Trust and the Manchester University NHS Foundation Trust. The pilot provides multidisciplinary diagnostic assessment and is informing the development of improved care pathways, including consideration of specialist multidisciplinary services to support earlier diagnosis, better coordination of care, and reduced reliance on emergency care. Initial learning was shared with NHS England in September 2025, with final recommendations expected this summer to inform decisions on any national commissioning, subject to funding.
Finally, whilst integrated care boards (ICBs) are the responsible commissioners of the majority of health services, including services related to medically induced disabilities, no specific guidance has been issued to ICBs in relation to supporting individuals with complex, medicine-induced disabilities arising from sodium valproate.
Asked by: Bob Blackman (Conservative - Harrow East)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what assessment has been made of the adequacy of the diagnostic time taken and levels of misdiagnosis among individuals harmed by sodium valproate, and its impact on long-term outcomes.
Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)
The Independent Medicines and Medical Devices Safety Review, First Do No Harm, identified significant shortcomings in National Health Service care pathways for people harmed by sodium valproate, including fragmented services, limited diagnostic expertise, delays in diagnosis, and inequitable access to multidisciplinary care. NHS England has acknowledged variation in the availability and adequacy of care pathways, the impact of delayed diagnosis and misdiagnosis on long-term outcomes, and the need for improved care coordination for those requiring lifelong support.
In response, NHS England has commissioned a Fetal Exposure to Medicines Services Pilot, being delivered by the Newcastle upon Tyne Hospitals NHS Foundation Trust and the Manchester University NHS Foundation Trust. The pilot provides multidisciplinary diagnostic assessment and is informing the development of improved care pathways, including consideration of specialist multidisciplinary services to support earlier diagnosis, better coordination of care, and reduced reliance on emergency care. Initial learning was shared with NHS England in September 2025, with final recommendations expected this summer to inform decisions on any national commissioning, subject to funding.
Finally, whilst integrated care boards (ICBs) are the responsible commissioners of the majority of health services, including services related to medically induced disabilities, no specific guidance has been issued to ICBs in relation to supporting individuals with complex, medicine-induced disabilities arising from sodium valproate.
Asked by: Bob Blackman (Conservative - Harrow East)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what assessment has been made of whether NHS care pathways are adequate for individuals harmed by sodium valproate that require lifelong, multidisciplinary care.
Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)
The Independent Medicines and Medical Devices Safety Review, First Do No Harm, identified significant shortcomings in National Health Service care pathways for people harmed by sodium valproate, including fragmented services, limited diagnostic expertise, delays in diagnosis, and inequitable access to multidisciplinary care. NHS England has acknowledged variation in the availability and adequacy of care pathways, the impact of delayed diagnosis and misdiagnosis on long-term outcomes, and the need for improved care coordination for those requiring lifelong support.
In response, NHS England has commissioned a Fetal Exposure to Medicines Services Pilot, being delivered by the Newcastle upon Tyne Hospitals NHS Foundation Trust and the Manchester University NHS Foundation Trust. The pilot provides multidisciplinary diagnostic assessment and is informing the development of improved care pathways, including consideration of specialist multidisciplinary services to support earlier diagnosis, better coordination of care, and reduced reliance on emergency care. Initial learning was shared with NHS England in September 2025, with final recommendations expected this summer to inform decisions on any national commissioning, subject to funding.
Finally, whilst integrated care boards (ICBs) are the responsible commissioners of the majority of health services, including services related to medically induced disabilities, no specific guidance has been issued to ICBs in relation to supporting individuals with complex, medicine-induced disabilities arising from sodium valproate.
Asked by: Bob Blackman (Conservative - Harrow East)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what guidance exists for Integrated Care Boards on supporting individuals with complex, medicine-induced disabilities arising from sodium valproate.
Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)
The Independent Medicines and Medical Devices Safety Review, First Do No Harm, identified significant shortcomings in National Health Service care pathways for people harmed by sodium valproate, including fragmented services, limited diagnostic expertise, delays in diagnosis, and inequitable access to multidisciplinary care. NHS England has acknowledged variation in the availability and adequacy of care pathways, the impact of delayed diagnosis and misdiagnosis on long-term outcomes, and the need for improved care coordination for those requiring lifelong support.
In response, NHS England has commissioned a Fetal Exposure to Medicines Services Pilot, being delivered by the Newcastle upon Tyne Hospitals NHS Foundation Trust and the Manchester University NHS Foundation Trust. The pilot provides multidisciplinary diagnostic assessment and is informing the development of improved care pathways, including consideration of specialist multidisciplinary services to support earlier diagnosis, better coordination of care, and reduced reliance on emergency care. Initial learning was shared with NHS England in September 2025, with final recommendations expected this summer to inform decisions on any national commissioning, subject to funding.
Finally, whilst integrated care boards (ICBs) are the responsible commissioners of the majority of health services, including services related to medically induced disabilities, no specific guidance has been issued to ICBs in relation to supporting individuals with complex, medicine-induced disabilities arising from sodium valproate.
Asked by: Bob Blackman (Conservative - Harrow East)
Question to the Department for Work and Pensions:
To ask the Secretary of State for Work and Pensions, whether Personal Independence Payment assessors receive specialist training on disabilities caused by sodium valproate.
Answered by Stephen Timms - Minister of State (Department for Work and Pensions)
The Department for Work and Pensions (DWP) is committed to ensuring that individuals with disabilities caused by sodium valproate receive high-quality, objective, and accurate assessments.
Personal Independence Payment (PIP) assessments are functional assessments designed to evaluate how an individual’s health conditions or impairments affect their ability to carry out daily living activities and mobility. Health professionals (HPs) conducting these assessments are trained specialists in disability analysis, focusing on understanding the functional impact of a claimant’s condition rather than its clinical diagnosis. DWP does not require HPs to be specialists in the specific medical conditions or impairments of those they assess.
Additionally, HPs have access to Condition Insight Reports and Continuing Professional Development guides. These resources offer detailed clinical and functional information on a range of conditions, including disabilities cause by sodium valproate such as, Fetal Valproate Spectrum Disorder (FVSD), to support HPs in delivering informed assessments.
Asked by: Bob Blackman (Conservative - Harrow East)
Question to the Department for Work and Pensions:
To ask the Secretary of State for Work and Pensions, what steps he has taken to reduce the level of incorrect Personal Independence Payment decisions for people with disabilities resulting from sodium valproate.
Answered by Stephen Timms - Minister of State (Department for Work and Pensions)
It is our aim to make the right decision as early as possible in the claim journey. To support this, we have made improvements to our decision-making processes to help ensure people get the support they are entitled to without needing to appeal. This includes giving Decision Makers additional time to proactively contact customers if they think additional evidence may support the claim.
Asked by: Bob Blackman (Conservative - Harrow East)
Question to the Department for Work and Pensions:
To ask the Secretary of State for Work and Pensions, what assessment he has made of the adequacy of payments received by unpaid carers for people harmed by sodium valproate.
Answered by Stephen Timms - Minister of State (Department for Work and Pensions)
People in Great Britain who provide unpaid care of 35 hours a week or more can receive financial support from the benefit system through Universal Credit (UC) or Pension Credit (PC). Carer’s Allowance (CA) is also available to those in England and Wales. UC and PC are means-tested and include additional amounts for carers worth around £2,400 a year. CA is not means-tested and is worth around £4,300 a year.
Payments to the unpaid carer are linked to the extra costs disability benefit received by the person with care needs. This is most commonly the Daily Living Component of Personal Independence Payment (PIP), the middle or highest rate Care Component of Disability Living Allowance (DLA), Attendance Allowance (AA), or the equivalent rates of Child Disability Payment, Adult Disability Payment, Scottish Adult Disability Living Allowance or Pension Age Disability Payment in Scotland. Receipt of PIP, DLA or AA is based on functional ability, rather than the health condition or disability itself. Individuals can be affected in different ways by the same condition, and so the outcome of a PIP claim from somebody harmed by sodium valproate would depend on individual circumstances. The amount of the carer additions in UC and PC, and the rate of CA, do not depend on the reason that the extra costs disability benefit is in payment.
Asked by: Caroline Johnson (Conservative - Sleaford and North Hykeham)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, whether he plans to inform families of his plans for (a) interim and (b) main payment compensation before the second anniversary of the publication of the Hughes Report.
Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)
The Government is carefully considering the work by the Patient Safety Commissioner and her report, which set out options for redress for those harmed by valproate and pelvic mesh.
This is a complex issue involving input from different Government departments. Since taking up my post, I have met with the patient safety commissioner to discuss her recommendations and discussed how we may respond in the near term to recommendations regarding improving the outcomes and lives of people harmed by Valproate and Pelvic mesh. The Government will provide a further update to the Patient Safety Commissioner’s report.